Eli Lilly (LLY) stock has plunged 33% in 2023, significantly underperforming the broader market. Several factors have contributed to this decline, including:
1. Patent Expiration and Generic Competition
- Eli Lilly’s blockbuster drug, Trulicity, is set to lose patent protection in 2025, paving the way for generic competition.
- Trulicity generated $7.7 billion in revenue in 2022, accounting for approximately 23% of Eli Lilly’s total sales.
- The loss of exclusivity for Trulicity is expected to significantly impact Eli Lilly’s top-line growth in the coming years.
2. Slowing Sales Growth
- Eli Lilly’s sales growth has decelerated in recent quarters due to increased competition and pandemic-related challenges.
- In the third quarter of 2023, the company reported total revenue of $8.1 billion, representing a mere 2% increase year-over-year.
- This slowdown in sales growth has raised concerns among investors about the company’s long-term growth prospects.
3. Clinical Trial Disappointment
- Eli Lilly suffered a major setback in February 2023 when its experimental Alzheimer’s drug, donanemab, failed to meet its primary endpoints in two Phase 3 clinical trials.
- This disappointing outcome cast doubt on the drug’s potential and led to a significant sell-off in Eli Lilly’s stock.
- The failure of donanemab is a significant blow to Eli Lilly’s pipeline and raises questions about the company’s ability to develop innovative new drugs.
4. Economic Headwinds
- The broader economic environment, characterized by rising interest rates and inflation, has also contributed to Eli Lilly’s stock decline.
- Investors are rotating out of growth stocks like Eli Lilly and into more defensive sectors.
- Uncertainty surrounding the global economy has weighed on investor sentiment and led to a sell-off in riskier assets.
Current Status and What We Can Do
Eli Lilly stock is currently trading at $300 per share, down from its 52-week high of $450. The company’s valuation has come down significantly, and it now trades at a price-to-earnings ratio of 20, which is below the industry average.
Despite the recent challenges, Eli Lilly remains a strong company with a solid pipeline of potential new drugs. The company’s diabetes franchise is still strong, and it has several other drugs in late-stage development.
Investors who believe in Eli Lilly’s long-term prospects may consider buying the stock at its current discounted price. However, they should be aware of the risks associated with the patent expiration of Trulicity and the potential for further setbacks in the company’s pipeline.
4 Ways to Generate Ideas for New Applications
- Brainstorming: Encourage team members to generate as many ideas as possible without judgment.
- Analogous thinking: Draw inspiration from existing solutions in other industries or contexts.
- SCAMPER: Use the SCAMPER technique to modify or improve existing solutions (substitute, combine, adapt, modify, put to another use, eliminate, reverse).
- Idea mapping: Create a visual representation of ideas, connecting them and exploring relationships.
